Floatz logo

Everolimus

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

OHSU Knight Cancer InstituteSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Rapamycin
OHSU Knight Cancer Institute
Phase 2B
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2B
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2B
Carboplatin
OHSU Knight Cancer Institute
Phase 2B

View all 50 →

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →